Related Experiment Video
Updated: Oct 30, 2025

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
Development of AC265347-Inspired Calcium-Sensing Receptor Ago-Positive Allosteric Modulators
Le Vi Dinh1,2, Aaron DeBono2, Andrew N Keller2
1Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University), 381 Royal Parade, Monash University, Parkville, VIC 3052, Australia.
Abstract:
The calcium-sensing receptor (CaSR) is a clinical target in the treatment of hyperparathyroidism and related diseases. However, clinical use of approved CaSR-targeting drugs such as cinacalcet is limited due to adverse side effects including hypocalcaemia, nausea and vomiting, and in some instances, a lack of efficacy. The CaSR agonist and positive allosteric modulator (ago-PAM), AC265347, is chemically distinct from clinically-approved CaSR PAMs. AC265347 potently suppressed parathyroid hormone (PTH) release in rats with a lower propensity to cause hypocalcaemia compared to cinacalcet and may therefore offer benefits over current CaSR PAMs. Here we report a structure activity relationship (SAR) study seeking to optimise AC265347 as a drug candidate and disclose the discovery of AC265347-like compounds with diverse pharmacology and improved physicochemical and drug-like properties.
Insights
Researchers optimized a novel calcium-sensing receptor (CaSR) agonist, AC265347, to improve hyperparathyroidism treatments. This study discovered new CaSR modulators with better drug properties and reduced side effects compared to existing therapies.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Endocrinology
Background:
- The calcium-sensing receptor (CaSR) is a key therapeutic target for hyperparathyroidism.
- Current CaSR modulators like cinacalcet have limitations including adverse effects and variable efficacy.
Purpose of the Study:
- To optimize the CaSR agonist AC265347 through structure-activity relationship (SAR) studies.
- To discover novel CaSR modulators with improved drug-like properties and reduced side effects.
Main Methods:
- Structure-activity relationship (SAR) analysis of AC265347.
- Pharmacological evaluation of novel CaSR modulators in preclinical models.
Main Results:
- AC265347 demonstrated potent suppression of parathyroid hormone (PTH) release in rats.
- AC265347 showed a reduced propensity for hypocalcaemia compared to cinacalcet.
- Discovery of novel AC265347-like compounds with diverse pharmacology and enhanced physicochemical properties.
Conclusions:
- Optimized CaSR modulators, derived from AC265347, hold promise for improved hyperparathyroidism treatment.
- These novel compounds may offer a better therapeutic window and reduced adverse effects compared to existing CaSR drugs.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
Related Concept Videos
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
GPCR Desensitization
GPCRs Regulate Adenylyl Cylase Activity
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Allosteric Regulation